Expression of SARS-Cov-2 Entry Factors in Patients with Chronic Hepatitis.
ACE2
NAFLD
SARS-Cov-2
TMPRSS2
chronic hepatitis
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
29 10 2022
29 10 2022
Historique:
received:
29
09
2022
revised:
26
10
2022
accepted:
27
10
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
15
11
2022
Statut:
epublish
Résumé
Chronic hepatitis (CH) of dysmetabolic or viral etiology has been associated with poor prognosis in patients who experienced the severe acute respiratory coronavirus virus-2 (SARS-Cov-2) infection. We aimed to explore the impact of SARS-Cov-2 infection on disease severity in a group of patients with CH. Forty-two patients with CH of different etiology were enrolled (median age, 56 years; male gender, 59%). ACE2 and TMPRSS2 were measured in plasma samples of all patients by ELISA and in the liver tissue of a subgroup of 15 patients by Western blot. Overall, 13 patients (31%) experienced SARS-Cov-2 infection: 2/15 (15%) had CHB, 5/12 (39%) had CHC, and 6/15 (46%) had non-alcoholic fatty liver disease (NAFLD). Compared to viral CH patients, NAFLD subjects showed higher circulating ACE2 levels (
Identifiants
pubmed: 36366497
pii: v14112397
doi: 10.3390/v14112397
pmc: PMC9699546
pii:
doi:
Substances chimiques
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Peptidyl-Dipeptidase A
EC 3.4.15.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Lancet Gastroenterol Hepatol. 2020 May;5(5):428-430
pubmed: 32145190
Gastroenterology. 2016 Apr;150(4):956-67
pubmed: 26764184
J Formos Med Assoc. 2020 Jun;119(6):1016-1018
pubmed: 32345544
Minerva Endocrinol (Torino). 2022 Sep;47(3):304-313
pubmed: 35195377
Sci Rep. 2020 Jan 21;10(1):887
pubmed: 31965023
Hepatology. 2005 Jun;41(6):1313-21
pubmed: 15915461
Hepatol Commun. 2022 Feb;6(2):270-280
pubmed: 34520633
Gastroenterology. 2002 Nov;123(5):1667-76
pubmed: 12404241
SN Compr Clin Med. 2020;2(8):1069-1076
pubmed: 32838147
J Hepatol. 2021 Feb;74(2):469-471
pubmed: 33096086
Nat Med. 2020 Jul;26(7):1017-1032
pubmed: 32651579
Protein Cell. 2020 Oct;11(10):771-775
pubmed: 32303993
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Hepatol Int. 2022 Aug;16(4):755-774
pubmed: 35767172
Kidney Int. 2012 Jun;81(12):1263-72
pubmed: 22418980
J Hepatol. 2020 Aug;73(2):451-453
pubmed: 32278005
Nat Commun. 2022 Jan 20;13(1):405
pubmed: 35058437
Hepatology. 2009 Sep;50(3):929-38
pubmed: 19650157
J Hepatol. 2020 Sep;73(3):718-719
pubmed: 32387073
Hepatology. 2016 Mar;63(3):731-44
pubmed: 26406121
Hepatol Commun. 2022 May;6(5):1056-1072
pubmed: 34951153
Cancers (Basel). 2021 Aug 13;13(16):
pubmed: 34439247
Front Physiol. 2021 Jul 14;12:707429
pubmed: 34335310
J Hepatol. 2018 Feb;68(2):238-250
pubmed: 29154966
Hepatol Commun. 2019 Oct 10;3(12):1656-1673
pubmed: 31832573
Lancet Gastroenterol Hepatol. 2020 Jul;5(7):667-678
pubmed: 32405603
Antioxid Redox Signal. 2022 Mar;36(7-9):480-504
pubmed: 34779230
Cell Stem Cell. 2020 Jul 2;27(1):125-136.e7
pubmed: 32579880
J Lipid Res. 2016 Feb;57(2):233-45
pubmed: 26621917
Gut. 2005 Dec;54(12):1790-6
pubmed: 16166274
J Am Soc Nephrol. 2009 Feb;20(2):363-79
pubmed: 19056867
Oxid Med Cell Longev. 2020 Jan 18;2020:4213541
pubmed: 32051731
Virol Sin. 2020 Dec;35(6):842-845
pubmed: 32839868
J Hepatol. 2019 Nov;71(5):1012-1021
pubmed: 31301321
Cell. 2021 Apr 15;184(8):2212-2228.e12
pubmed: 33713620